Preprint / Version 1

A Review of Creutzfeldt-Jakob Disease: Biology, Development, and Current Research

##article.authors##

  • Iris Li Texas Academy of Mathematics and Science

DOI:

https://doi.org/10.58445/rars.2699

Keywords:

Creutzfeldt-Jakob disease, Prions, neurodegenerative diseases

Abstract

Creutzfeldt-Jakob disease (CJD) is a rare, fatal neurodegenerative disorder caused by prions—abnormally folded proteins. Unlike typical infectious agents, prions lack genetic material and are exceptionally resistant to sterilization. CJD manifests through progressive neurological and psychological symptoms, ultimately resulting in death. It can develop sporadically,
genetically, iatrogenically, or through contaminated food. Although no cure currently exists, recent research has shown promising results, including the recent human trial of the monoclonal antibody PRN100. This paper provides an overview of prion biology, the development of CJD, and recent therapeutic research.

References

National Health Service. (n.d.). Creutzfeldt-Jakob disease: Symptoms.

https://www.nhs.uk/conditions/creutzfeldt-jakob-disease-cjd/symptoms/

National Health Service. (n.d.). Creutzfeldt-Jakob disease: Causes.

https://www.nhs.uk/conditions/creutzfeldt-jakob-disease-cjd/causes/

Prion. (2025, June 22). In Wikipedia. https://en.wikipedia.org/wiki/Prion

Centers for Disease Control and Prevention. (2024, May). Classic Creutzfeldt-Jakob disease.

https://www.cdc.gov/creutzfeldt-jakob/about/index.html

LibreTexts. (2023, September 13). 4.6.3: Prions. In Biology LibreTexts.

https://bio.libretexts.org/Courses/Northwest_University/MKBN211%3A_Introductory_Microbiolog

y_(Bezuidenhout)/04%3A_Viruses/4.06%3A_Subviral_Entities/4.6.03%3A_Prions

Mead, S., Khalili-Shirazi, A., Potter, C., Mok, T., Nihat, A., Hyare, H., Canning, S., Schmidt,

C., Campbell, T., Darwent, L., Muirhead, N., Ebsworth, N., Hextall, P., Wakeling, M., Linehan, J.,

Libri, V., Williams, B., Jaunmuktane, Z., Brandner, S., ... Rudge, P. (2022). Prion protein

monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: Evaluation of a

first-in-human treatment programme. The Lancet Neurology, 21(4), 342–354.

https://doi.org/10.1016/s1474-4422(22)00082-5

Downloads

Posted

2025-07-04